4-Allyl-3-(2-methyl-4-quinol­yl)-1H-1,2,4-triazole-5(4H)-thione

In the title compound, C15H14N4S, the quinoline and triazole rings form a dihedral angle of 41.48 (7)°. In the crystal, adjacent mol­ecules are linked by N—H⋯N hydrogen bonds, forming chains along [100]

Methyl 4-methyl-2-oxo-1,2,5,6-tetra­hydro-4H-pyrrolo[3,2,1-ij]quinoline-6-carboxyl­ate

In the title mol­ecule, C14H15NO3, the six-membered heterocyclic ring exhibits an envelope conformation. In the crystal, C—H⋯π inter­actions link the mol­ecules into centrosymmetric dimers, and weak inter­molecular C—H⋯O hydrogen bonds link these dimers into columns propagated along [100]

CAPABILITIES OF ENDOSCOPIC ORGAN PRESERVATION TREATMENT OF INVASIVE BLADDER CANCER PATIENTS AT THE STAGE Ò2àN0M0

The  combination  of the transurethral  vaporization,  transurethral  resection  of bladder cancer  together with the combined chemotherapy was applied( patent application no. 2010127350/20 (038956) d.d. 5.07.10 “Bladder cancer  treatment method”). The developed system of a pseudo-multifactorial analysis was used to study the treatment results. The study proves that the combination of the transurethral resection and transurethral vaporization lets decrease both the number of bladder cancer  recurrences and the number of complications. The treatment of bladder cancer  patients at the stage Т2аN0M0 with the application of the systemic polychemotherapy and doxorubicin adjuvant chemotherapy according to the schedule lets the recurrence free survival get 93.0%. The results of our research prove the competence of the endoscopic organ preservation treatment to be applied to treat invasive cancers

ВОЗМОЖНОСТИ ЭНДОСКОПИЧЕСКОГО ОРГАНОСОХРАНЯЩЕГО ЛЕЧЕНИЯ БОЛЬНЫХ ИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯ Т2аN0M0

The  combination  of the transurethral  vaporization,  transurethral  resection  of bladder cancer  together with the combined chemotherapy was applied( patent application no. 2010127350/20 (038956) d.d. 5.07.10 “Bladder cancer  treatment method”). The developed system of a pseudo-multifactorial analysis was used to study the treatment results. The study proves that the combination of the transurethral resection and transurethral vaporization lets decrease both the number of bladder cancer  recurrences and the number of complications. The treatment of bladder cancer  patients at the stage Т2аN0M0 with the application of the systemic polychemotherapy and doxorubicin adjuvant chemotherapy according to the schedule lets the recurrence free survival get 93.0%. The results of our research prove the competence of the endoscopic organ preservation treatment to be applied to treat invasive cancers.Применили в лечение пациентов с раком  мочевого пузыря  стадии  Т2аN0M0  сочетание  трансуретральной вапоризации с трансуретральной резекцией и комбинированную химиотерапию (заявка на патент №2010127350/20 (038956) от 5.07.10 «Способ лечения  при  раке  мочевого пузыря»). При анализе результатов лечения  применили разработанную систему  псевдомногофакторного анализа. В исследовании доказано, что использование сочетания  трансуретральной резекции и  вапоризации позволяет снизить  количество рецидивов рака  мочевого пузыря,  снизить  количество осложнений.  Применение в лечение пациентов с раком  мочевого пузыря  стадий  Т2аN0M0 ТУР+ТУЭВ, системной полихимиотерапии и внутрипузырной адъювантной химиотерапии  доксирубицином по схеме позволяет достичь  безрецидивной выживаемости в 93,0% случаев.  Результаты  нашего  исследования показали правомочность применения эндоскопического органосохраняющего лечения  при инвазивных опухолях

URINARY INCONTINENCE AFTER HIFU PROSTATE CANCER TREATMENT

The  use  of  HIFU for  prostate cancer   treatment causes   a  significant number  of complications in the  form  of urinary incontinence, which responds poorly to conservative therapy and  reduces the  quality of life. Our results  suggest the  need  rigorous  evaluation of  the  indications for  this method of  treatment, careful  patient selection  excluding  the evidence of obstruction, and the search for effective treatments for urinary incontinence.The study identified a set of independent prognostic risk factors for urinary incontinence, which formed the basis of a mathematical model and computer program for estimating the risk of urinary incontinence after HIFU therapy. This program can be used to determine the likelihood of disease in clinical practice, and these data are the basis of a set of measures for the prevention of urinary incontinence after HIFU therapy